atenolol has been researched along with nisoldipine in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.26) | 18.7374 |
| 1990's | 6 (31.58) | 18.2507 |
| 2000's | 5 (26.32) | 29.6817 |
| 2010's | 7 (36.84) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Bruno-Blanch, L; Gálvez, J; García-Domenech, R | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Elliott, HL; McNally, C; Meredith, PA; Reid, JL | 1 |
| Kantor, M; Pedersen, TR | 1 |
| Fukuyama, M; Okabayashi, H; Takahashi, H; Yoneda, S; Yoshimura, M | 1 |
| Ishimitsu, T; Ogawa, Y; Oka, K; Ono, H; Tsukada, H; Yagi, S | 1 |
| Dawkins, KD; Donaldson, KM; Waller, DG | 2 |
| Earle, KA; Hoffbrand, BI; Nievel, JG; Restrick, LJ; Simmonds, NJ | 1 |
1 review(s) available for atenolol and nisoldipine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 trial(s) available for atenolol and nisoldipine
| Article | Year |
|---|---|
The interactions between nisoldipine and two beta-adrenoceptor antagonists--atenolol and propranolol.
Topics: Adult; Atenolol; Blood Pressure; Drug Interactions; Exercise; Heart Rate; Humans; Kidney; Liver; Male; Nisoldipine; Propranolol; Reference Values; Regional Blood Flow | 1991 |
Nisoldipine tablets once daily versus nifedipine capsules three times daily in patients with stable effort angina pectoris pretreated with atenolol.
Topics: Adult; Angina Pectoris; Atenolol; Blood Pressure; Capsules; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Exercise Test; Female; Heart Rate; Humans; Male; Middle Aged; Nifedipine; Nisoldipine; Tablets | 1990 |
Comparison of nisoldipine and atenolol in the treatment of essential hypertension.
Topics: Adult; Aged; Atenolol; Blood Pressure; Calcium Channel Blockers; Captopril; Heart Rate; Humans; Hypertension; Male; Middle Aged; Nifedipine; Nisoldipine; Random Allocation; Renin; Stress, Physiological | 1989 |
A comparison of nisoldipine and nifedipine, in combination with atenolol, in the management of myocardial ischaemia.
Topics: Adult; Aged; Angina Pectoris; Atenolol; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Electrocardiography, Ambulatory; Exercise Test; Female; Humans; Male; Middle Aged; Nifedipine; Nisoldipine | 1993 |
Comparison of nisoldipine and nifedipine as additional treatment in hypertension inadequately controlled by atenolol.
Topics: Atenolol; Black People; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Nifedipine; Nisoldipine; Triglycerides; White People | 1993 |
A comparison of the acute haemodynamic effects of nisoldipine and nifedipine during treatment with atenolol in patients with coronary artery disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Atenolol; Blood Pressure; Calcium Channel Blockers; Cardiac Catheterization; Cardiac Output; Coronary Artery Disease; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Heart Rate; Humans; Infusions, Intravenous; Male; Middle Aged; Nifedipine; Nisoldipine; Single-Blind Method; Vascular Resistance | 1993 |
12 other study(ies) available for atenolol and nisoldipine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
Topics: Anticonvulsants; Computer Simulation; Databases, Factual; Discriminant Analysis; Drug Design; Molecular Structure; Quantitative Structure-Activity Relationship | 2003 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Renoprotective effect of nisoldipine in rats with severe hypertension.
Topics: Animals; Aorta; Arterioles; Atenolol; Blood Pressure; Creatinine; Desoxycorticosterone; Enalapril; Hypertension; Kidney; Male; Myocardium; Nisoldipine; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Renal Circulation; Sodium Chloride | 1994 |